Specialty Pharmacy

Cost of premiums, deductibles, and copays listed as important factors in choosing health plans.

Agreement with Immune Design could expand the potential of immunotherapy through combination approaches.

Onsolis provides opioid tolerant patients with an alternative dosing option.

Compound targets latent HIV proteins without harming other parts of the body.

Drug reduced chorea and writhing movements in patients afflicted with the disease.

Ethicists worried trials will threaten scientific rigor and efficacy.

Screening evaluates a large number of cells used in cancer therapy.

States need to target specific populations affected by HIV outbreaks.

Research advances personalized cancer therapy.

Religion and spirituality can have a positive impact on cancer outcomes.

MS comorbidities increase the risk of early mortality.

FDA-approved drug is now a first-line treatment for select patients with EGFR non-small cell lung cancer.

New treatment approach many help control inflammation.

Comorbidities lead to more complex treatment and higher costs.

David Lassen, chief clinical officer at Prime Therapeutics, discusses changes in store for the field of specialty pharmacy in the coming years.

Additional benefit from dasabuvir and combination of ombitasvir/paritaprevir/ritonavir found in pretreated genotype 1b hepatitis C patients without cirrhosis.

Research may help to target which patients will respond to specific chemotherapy drugs.

Inhibiting oxygen sensor leads to a reduced spread of breast cancer throughout the body.

Majority of participants experienced no spontaneous joint bleeding episodes.

Hepatitis C drugs with high cure rates create new dilemma for people in need of transplantation.

Patient experiences complete remission after treatment with 2 immunotherapies.

Patient who make multiple trips to their general practitioner before getting a diagnosis are more likely to respond negatively to other aspects of their care.

Roche is seeking FDA premarket approval of its companion diagnostic test for AstraZeneca's investigational therapy for non-small cell lung cancer patients with an acquired resistant mutation.

The public fear of human immunodeficiency virus has diminished since the 1980s crisis, and now many health care professionals are seeing less urgency surrounding HIV prevention and treatment.

Salt found to influence immune cells that cause the disease.

Nivolumab shows promise in patients whose disease progressed after ipilimumab and BRAF inhibitor therapy.

Catch up with the latest developments in cancer research.

Weight cycling may influence the biological processes that can lead to cancer.